{
  "id": 7267742,
  "title": "U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations",
  "url": "https://urgent.news/2026/09/14/u-s-fda-accepts-new-drug-application-under-priority-review-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T07:02:45.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/u-s-fda-accepts-new-drug-application-under-priority-review-for-takedas-zasocitinib-in-moderate-to-severe-plaque-psoriasis-with-potential-to-redefine-oral-treatment-expectations"
  },
  "original_language": "en",
  "account": null,
  "summary": "Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}